About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT06928818

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea

Lead sponsor: Seoul National University Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Kyung-Hun Lee, MD, PhD

CONTACT

82-2-2072-7207 [email protected]

Sponsors

Lead Sponsor

Seoul National University Hospital

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer
•Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting
•Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression

Exclusion Criteria

•Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)
•Has been previously treated with T-DM1 for advanced breast cancer
•Has been previously treated with 4 or more lines of therapy for advanced breast cancer
•* Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).

Related studies

RECRUITINGPhase 2

Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan

NCT07537673 · Nausea and Vomiting Caused by Trastuzumab Deruxtecan

RECRUITINGPhase 1/2

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

NCT06471673 · Breast Cancer, Breast Tumor, and more

RECRUITINGPhase 2

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

NCT06125834 · Advanced Breast Cancer, Objective Response Rate, and more

Active Not RecruitingNA

Telehealth Weight Loss Program for Breast Cancer Survivors

NCT04855552 · Cancer Survivors, Cancer of Breast, and more

COMPLETEDPhase 2

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT03084536 · Breast Cancer, Breast Cancer Female, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 23, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment100

Start dateFeb 2025

Last updatedApr 23, 2026

Condition

Cancer of Breast Trastuzumab Emtansine Trastuzumab Deruxtecan

Locations shown

Seoul National University Hospital

Seoul

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 23, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions